235 related articles for article (PubMed ID: 25926115)
1. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Feb; 59(1):54-8. PubMed ID: 25926115
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L.
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2017; 61(5):426-431. PubMed ID: 28977166
[TBL] [Abstract][Full Text] [Related]
3. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
4. Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2016; 60(6):510-514. PubMed ID: 27982199
[TBL] [Abstract][Full Text] [Related]
5. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
6. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
8. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
9. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
10. Remission criteria for the follow-up of patients with acromegaly.
Gullu S; Keles H; Delibasi T; Tonyukuk V; Kamel N; Erdogan G
Eur J Endocrinol; 2004 Apr; 150(4):465-71. PubMed ID: 15080775
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
12. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
13. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
14. Gender- and age-related differences in the endocrine parameters of acromegaly.
Colao A; Amato G; Pedroncelli AM; Baldelli R; Grottoli S; Gasco V; Petretta M; Carella C; Pagani G; Tambura G; Lombardi G
J Endocrinol Invest; 2002 Jun; 25(6):532-8. PubMed ID: 12109625
[TBL] [Abstract][Full Text] [Related]
15. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
Gutt B; Hatzack C; Morrison K; Pöllinger B; Schopohl J
Eur J Endocrinol; 2001 Feb; 144(2):109-16. PubMed ID: 11182746
[TBL] [Abstract][Full Text] [Related]
16. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
18. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
19. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
[TBL] [Abstract][Full Text] [Related]
20. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
